Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see ...

Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by weight loss, loss of muscle mass, fatigue, and lack of appetite, and is ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

The Pfizer-sponsored study enrolled 187 participants across the world — including 10 from Oregon Health & Science University, ...

Pfizer Inc.'s experimental drug for cancer weight loss was shown to help patients regain weight in a mid-stage study, ...

Ponsegromab, a monoclonal antibody treatment from Pfizer, showed promising results in a clinical study aimed at treating the wasting condition cachexia in cancer patients. Patients treated with ...

A phase 2 trial of ponsegromab has shown promising results in treating cancer cachexia, a condition that leads to severe weight and muscle loss, according to a study published Sept. 14 in the New ...